- Home
- MTG vs MDGL Comparison
MTG vs MDGL Comparison
Compare MTG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTG
- MDGL
- Stock Information
- Founded
- MTG 1957
- MDGL 2011
- Country
- MTG United States
- MDGL United States
- Employees
- MTG N/A
- MDGL N/A
- Industry
- MTG Property-Casualty Insurers
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- MTG Finance
- MDGL Health Care
- Exchange
- MTG Nasdaq
- MDGL Nasdaq
- Market Cap
- MTG 6.4B
- MDGL 6.1B
- IPO Year
- MTG 1991
- MDGL N/A
- Fundamental
- Price
- MTG $27.51
- MDGL $369.84
- Analyst Decision
- MTG Hold
- MDGL Strong Buy
- Analyst Count
- MTG 6
- MDGL 8
- Target Price
- MTG $26.67
- MDGL $439.71
- AVG Volume (30 Days)
- MTG 2.2M
- MDGL 425.4K
- Earning Date
- MTG 07-30-2025
- MDGL 08-05-2025
- Dividend Yield
- MTG 2.18%
- MDGL N/A
- EPS Growth
- MTG 12.94
- MDGL N/A
- EPS
- MTG 3.05
- MDGL N/A
- Revenue
- MTG $1,218,572,000.00
- MDGL $515,547,000.00
- Revenue This Year
- MTG $2.92
- MDGL $286.67
- Revenue Next Year
- MTG $3.06
- MDGL $67.98
- P/E Ratio
- MTG $9.02
- MDGL N/A
- Revenue Growth
- MTG 3.26
- MDGL 3421.98
- 52 Week Low
- MTG $21.94
- MDGL $200.63
- 52 Week High
- MTG $28.67
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- MTG 60.54
- MDGL 72.27
- Support Level
- MTG $26.38
- MDGL $286.44
- Resistance Level
- MTG $27.20
- MDGL $375.67
- Average True Range (ATR)
- MTG 0.47
- MDGL 14.59
- MACD
- MTG 0.19
- MDGL 5.47
- Stochastic Oscillator
- MTG 83.90
- MDGL 93.47
About MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.